v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 49,232 $ 30,624
General and administrative 8,754 4,249
Total operating expenses 57,986 34,873
Loss from operations (57,986) (34,873)
Other income:    
Interest income 4,776 4,524
Other income (loss) 121 (40)
Total other income 4,897 4,484
Net loss $ (53,089) $ (30,389)
Net loss per share, basic (in dollars per share) $ (0.52) $ (0.36)
Net loss per share, diluted (in dollars per share) $ (0.52) $ (0.36)
Weighted average shares used to compute net loss per share, basic (in shares) [1] 102,800,098 85,426,223
Weighted average shares used to compute net loss per share, diluted (in shares) [1] 102,800,098 85,426,223
[1] Reflects the weighted average effect of the pre-funded warrants on the calculation of basic and diluted net loss per share.